Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

2011/05/04 by Naomi Schlesinger, Eduardo Mysler, Hsiao‐Yi Lin +10 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Gout, Hyperuricemia, Uric Acid #Rheumatoid Arthritis Research and Therapies #Inflammasome and immune disorders

paper · pdf · doi:10.1136/ard.2010.144063

Citations

• The pathogenesis of bone erosions in gouty arthritis

Cited by

• A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation? [europepmc]
• Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. [europepmc]
• Uric acid as a danger signal in gout and its comorbidities. [europepmc]
• 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. [europepmc]
• Targeting interleukin-1 in heart disease. [europepmc]
• Treating inflammation by blocking interleukin-1 in humans. [europepmc]
• Outcome measures in acute gout: a systematic literature review. [europepmc]
• IL-1 blockade in autoinflammatory syndromes. [europepmc]
• Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. [europepmc]
• Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. [europepmc]
• IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice. [europepmc]
• Colchicine for prevention of cardiovascular events. [europepmc]
• Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis. [europepmc]
• Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. [europepmc]
• 2020 American College of Rheumatology Guideline for the Management of Gout. [europepmc]
• NLRP3 Inflammasome in Inflammation and Metabolism: Identifying Novel Roles in Postburn Adipose Dysfunction. [europepmc]
• The NLRP3 Inflammasome: Role and Therapeutic Potential in Pain Treatment. [europepmc]
• Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now? [europepmc]
• Colchicine for acute gout. [europepmc]
• The Interaction Between Dietary Fructose and Gut Microbiota in Hyperuricemia and Gout. [europepmc]
• Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. [europepmc]
• The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout. [europepmc]
• Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review. [europepmc]
• Mastoparan M Suppressed NLRP3 Inflammasome Activation by Inhibiting MAPK/NF-κB and Oxidative Stress in Gouty Arthritis. [europepmc]
• Targeting the NLRP3 inflammasome for inflammatory disease therapy. [europepmc]